Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

Sophie RocaDepartment of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital-CHU Bordeaux, France

Amandine QuivyDepartment of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital-CHU Bordeaux, France

Marine Gross-GoupilDepartment of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital-CHU Bordeaux, France

Jean-Christophe BernhardDepartment of Urology, Hôpital Pellegrin, Bordeaux University Hospital-CHU Bordeaux, France

Henri De ClermontDepartment of Nuclear Medecine, Hôpital Pellegrin, Bordeaux University Hospital-CHU Bordeaux, France

Alain RavaudDepartment of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital-CHU Bordeaux, France;University of Bordeaux 2 (Victor Segalen), Bordeaux, France;Clinical Investigational Center (CIC), INSERM 005, Bordeaux, FranceCorrespondence[email protected]

References

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, . RECORD-1 Study Group: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256–65.
PubMed Web of Science ®Google Scholar
Ravaud A, Digue L, Trufflandier N, Smith D. VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol 2010;21: 431–2.
PubMed Web of Science ®Google Scholar
Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, . Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010;116:5400–6.
PubMed Web of Science ®Google Scholar
Grünwald V, Seidel C, Fenner M, Heuser M, Ganser A. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Proc ASCO GU 2010; abstr 414.
Google Scholar
Bracarda S, Ravaud A, Chioidi M. Mammalian target of rapamycin inhibitors in clinical practice: Case reports of everolimus in renal cell carcinoma. Eur Urol 2009;8:815–9.
Web of Science ®Google Scholar
Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011;16:32–44.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date